Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Analysts at HC Wainwright boosted their FY2026 EPS estimates for shares of Enliven Therapeutics in a research report issued on Friday, November 13th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($1.62) per share for the year, up from their prior estimate of ($1.74). HC Wainwright has a "Buy" rating and a $73.00 price target on the stock. The consensus estimate for Enliven Therapeutics' current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Enliven Therapeutics' Q4 2026 earnings at ($0.40) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.46) EPS, Q4 2027 earnings at ($0.48) EPS and FY2027 earnings at ($1.80) EPS.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09.
Other equities research analysts have also issued reports about the stock. Zacks Research upgraded shares of Enliven Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, November 11th. William Blair assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, August 18th. They set an "outperform" rating on the stock. JPMorgan Chase & Co. initiated coverage on shares of Enliven Therapeutics in a research report on Thursday, October 1st. They set an "overweight" rating and a $75.00 price objective on the stock. Barclays initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They set an "overweight" rating and a $78.00 price objective for the company. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Thursday, October 15th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $75.44.
Read Our Latest Research Report on Enliven Therapeutics
Enliven Therapeutics Stock Performance
ELVN stock opened at $47.62 on Tuesday. The company's 50 day moving average is $46.20 and its 200 day moving average is $43.78. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $62.32.
Insider Buying and Selling at Enliven Therapeutics
In other news, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the transaction, the director owned 13,000 shares in the company, valued at approximately $606,710. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 6,018 shares of the business's stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $38.48, for a total value of $231,572.64. Following the completion of the sale, the chief financial officer directly owned 38,000 shares of the company's stock, valued at approximately $1,462,240. This trade represents a 13.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 25,036 shares of company stock worth $1,141,289. 3.00% of the stock is owned by insiders.
Hedge Funds Weigh In On Enliven Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV bought a new position in shares of Enliven Therapeutics in the first quarter worth approximately $38,000. Three Bridge Wealth Advisors LLC bought a new stake in Enliven Therapeutics during the 3rd quarter valued at $53,000. Sterling Capital Management LLC raised its holdings in Enliven Therapeutics by 1,180.7% during the 3rd quarter. Sterling Capital Management LLC now owns 1,921 shares of the company's stock valued at $88,000 after buying an additional 1,771 shares during the last quarter. State of Wyoming bought a new stake in Enliven Therapeutics during the 2nd quarter valued at $96,000. Finally, FNY Investment Advisers LLC purchased a new stake in Enliven Therapeutics during the 2nd quarter valued at $126,000. 95.08% of the stock is currently owned by institutional investors.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth. The company's pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2. Enliven is based in Boulder, Colorado.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.